• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of Computational Sciences

    4/4/22 8:00:00 AM ET
    $JNJ
    $LH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $JNJ alert in real time by email

    Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today the appointment of Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005164/en/

    Victor Lobanov, Ph.D., Ventus Senior Vice President, Head of Computational Sciences (Photo: Business Wire)

    Victor Lobanov, Ph.D., Ventus Senior Vice President, Head of Computational Sciences (Photo: Business Wire)

    Dr. Lobanov brings to Ventus more than 25 years of experience in developing and implementing leading-edge computational methods across the drug discovery continuum. He has unique expertise in machine-learning, artificial intelligence, and computational chemistry, all critical aspects of the ReSOLVE platform. At Ventus, Dr. Lobanov will oversee all scientific and operational aspects of computational sciences and information technology. He will focus on driving the rapid growth of Ventus' internal computational capabilities and also help direct the strategy for extending the scope and application of Ventus' ReSOLVE platform.

    "ReSOLVE integrates unique capabilities in structural biology, physics-based in-silico modeling, and machine learning, and is embedded in our drug discovery organization. Victor has an extraordinary track record of growing and leading teams to build and scale up innovative technologies in these very areas. We believe his expertise is ideally suited to Ventus' strategy and a wonderful complement to our renowned scientific advisors and internal computational leaders," said Marcelo Bigal, M.D., Ph.D., president and CEO of Ventus.

    Michael Crackower, Ph.D., Chief Scientific Officer of Ventus added: "Victor brings a depth of valuable expertise developing computational and machine learning platforms across multiple scientific disciplines. He is a rare individual with expertise in physics-based drug design and compound library development, as well as cutting-edge machine learning. His leadership will be critical to further expanding the moat around ReSOLVE, to identify and develop complementary approaches to build the computational capabilities of Ventus, and to attract other field-leading scientists and engineers to our growing organization."

    Dr. Lobanov has deep expertise across chemistry, cheminformatics, computational chemistry, machine learning and clinical trial operations, leading the delivery of innovative solutions for drug discovery and development. After receiving his Ph.D. in computational chemistry from the University of Tartu in Estonia, he conducted post-doctoral research in cheminformatics at the University of Florida. Early in his career, Dr. Lobanov worked at 3-Dimensional Pharmaceuticals (acquired by J&J) where he developed computational programs for drug design and discovery, incorporating machine learning methods. Dr. Lobanov had a decade-long tenure at Johnson & Johnson (NYSE:JNJ), where he played leadership roles in the Informatics Center of Excellence and in Pharma R&D IT; his accomplishments include the design, development, and implementation of an industry-first enterprise-wide discovery informatics platform utilized by the entire J&J/Janssen R&D organization. Dr. Lobanov joins Ventus from Labcorp Drug Development (NYSE:LH), where he served as Vice President, Informatics Solution Development, leading Xcellerate technology development focused on applying machine learning and data science for clinical trial optimization.

    "I believe that Ventus has created something unique with the ReSOLVE platform, as I view it as a first-of-its-kind physics-based computational chemistry platform that utilizes advanced and unique solvation modeling tools to transform virtual screening. This advanced platform capability is fully integrated into a small molecule drug discovery organization with strong structural biology capabilities. I look forward to supporting Ventus in becoming a leading company in targeting difficult to drug proteins. It is a privilege to join an organization with the potential to create an unmatched pipeline of new medicines," said Dr. Lobanov.

    About Ventus Therapeutics

    Ventus Therapeutics is a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of diseases, with an initial focus on immunology, inflammation, and neurology. We have developed a proprietary drug discovery platform, called ReSOLVE, which is built upon our structural biology and protein science expertise and our proprietary computational chemistry capabilities, to address the current limitations of small molecule drug discovery. We are leveraging our ReSOLVE platform to discover and characterize previously unknown or poorly understood pockets on the surface of proteins and identify small molecules that can bind to those pockets with optimal affinity. We are focused on high-value targets that have been extensively implicated in human diseases but were previously considered undruggable or where we believe there is a significant opportunity to improve upon existing therapies. Our lead programs target key innate immune modulators, including NLRP3 and cGAS. For more information, please visit www.ventustx.com and engage with us on Twitter @Ventus_Tx or on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of executive leadership team additions, our business strategy, current programs, and timing of planned preclinical and clinical activities and future results of operations and financial position. These forward-looking statements are based on our current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress and results of preclinical and clinical studies involving our development programs; the results of our earlier studies not being predictive of future results; our ability to enhance the ReSOLVE platform; our ability to continue to obtain funding for our operations and implement our business strategy; the impact of the COVID-19 pandemic on our business and our efforts to address its impact on our business; anticipated developments related to our competitors and our industry; the performance of third-party service providers, including suppliers and manufacturers; and our ability to obtain, maintain and protect our intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and we undertake no duty or obligation to update any forward-looking statements as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005164/en/

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $LH

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Labcorp Holdings Inc.
    $LH
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Labcorp Holdings Inc.
    $LH
    4/2/2025$276.00Buy
    Redburn Atlantic
    Labcorp Holdings Inc.
    $LH
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    More analyst ratings

    $JNJ
    $LH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Johnson & Johnson from Equal Weight to Overweight and set a new price target of $212.00

    10/3/25 8:30:20 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Innovative Medicine, R&D Reed John C exercised 21,721 shares at a strike of $157.92 and sold $4,185,793 worth of shares (21,721 units at $192.71) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    10/20/25 7:13:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Morikis John G claimed ownership of 599 shares (SEC Form 3)

    3 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/15/25 4:36:54 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/11/25 5:52:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence

    New case study shows how a streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence Praia Health, a patient experience orchestration platform for health systems, Providence, one of the nation's largest health systems, and Labcorp, a global leader of innovative and comprehensive laboratory services, announced today outcomes from a collaboration that significantly improved lab appointment adherence, patient engagement, and operational efficiency at Providence. Providence identified an opportunity to create a more streamlined and supportive lab booking process for patients. To achieve this, Providence connected its Pra

    10/20/25 9:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

    Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, N.J., Oct. 19, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and plat

    10/19/25 10:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

    First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results RARITAN, N.J., Oct. 16, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-3 study. The study evaluates the efficacy and safety of TECVAYLI® (teclistamab-cqyv) in com

    10/16/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    10/14/25 7:22:58 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    10/8/25 4:20:31 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    9/25/25 4:29:14 PM ET
    $LH
    Medical Specialities
    Health Care

    $JNJ
    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquel

    10/14/25 6:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business

    Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes Johnson & Johnson (the "Company") (NYSE:JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operational focus of each company and drive value for stakeholders. The intended separation would further strengthen the focus of Johnson & Johnson as an in

    10/14/25 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook

    2025 Third-Quarter reported sales growth of 6.8% to $24.0 Billion with operational growth of 5.4%* and adjusted operational growth of 4.4%* 2025 Third-Quarter reflects earnings per share (EPS) of $2.12 and adjusted EPS of $2.80 Significant innovation including approvals of INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA subcutaneous in ulcerative colitis, submission of icotrokinra for plaque psoriasis, landmark data for RYBREVANT plus LAZCLUZE overall survival in non-small cell lung cancer, and DanGer Shock long-term survival benefit of Impella Heart Pump Company increases full year estimated reported sales5 guidance to $93.7B or 5.7% at the midpoint; reaffirm

    10/14/25 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services